Archive for the ‘cancer biology’ Category
The chair of a biology department who has faced years of misconduct accusations has taken another hit—a lengthy correction due to text “overlap” between one of his PNAS papers and six other articles.
According to the correction, a reader contacted the journal to notify the editors that text and sentences in multiple sections of the 2015 paper — on which Carlo Croce is last author — were lifted from other sources without quotation marks.
This is the second correction for Croce in PNAS regarding overlap issues in just the last few weeks—the first was published on March 7 (see here). In both instances, PNAS did not call the textual similarities plagiarism, but the notice details multiple instances of overlap.
Croce, the chair of the department of cancer biology and genetics at The Ohio State University (OSU), is no stranger to controversy.
Here’s a rather odd case: When readers raised issues about some of the images in a 2008 cancer paper, the authors issued a correction last year. But when readers asked additional questions about the corrected images, the authors decided to retract the paper entirely, along with its correction.
Here’s the retraction notice for the 2008 article “PRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2,” published in Oncogene, which includes a link to the July 2016 correction: Read the rest of this entry »
Today isn’t a great day for Carlo Croce, chair of the department of cancer biology and genetics at The Ohio State University (OSU).
The New York Times has a lengthy article detailing the misconduct accusations that have swirled around Croce for years. We’ve covered many, but The Gray Lady obtained documents that show there have been many more.
The story mentions a 2013 letter from Ohio State University to pseudonymous whistleblower Clare Francis (which we reported on in 2014), acknowledging Francis’s allegations against Croce. However, in the letter, an administrator said OSU saw no reason to investigate Croce.
The story didn’t stop there, as the Times reports:
Pfizer has retracted a paper by a former employee who was fired after the company discovered she had been doctoring data.
The retraction, in Molecular Cancer Research, is the third of five papers Pfizer asked to retract, after an investigation discovered they contained duplicated images. The papers have been discussed on PubPeer, which is also mentioned in the latest retraction notice.
As a result of the investigation, Pfizer terminated the employment of Min-Jean Yin, the last author on the newly retracted paper.
According to the notice, Yin and five of her co-authors agreed to the retraction:
A cancer biologist based at the University of Maryland is transitioning out of research, as a journal has retracted three more of his papers.
Anil Jaiswal has now lost 13 papers, including, as we reported on February 6, six retractions issued earlier this month.
The Baltimore Sun reported this week that Jaiswal would no longer be conducting research at the University of Maryland School of Medicine, which we confirmed from a spokesperson:
A journal has retracted six papers by a cancer researcher at the University of Maryland in Baltimore, bringing his total to 10.
The retractions cite an investigation by the university, and detail problems ranging from duplicated images, to tweaking an image to conceal particular bands, to including unreliable data.
Three of the papers had already been flagged by the journal with expressions of concern. The last author on all the papers is Anil Jaiswal, a professor in the pharmacology department. He has issued four previous retractions.
Bruce Jarrell, the Chief Academic and Research Officer and Senior Vice President at the University of Maryland, told us at least two more retractions are forthcoming:
Sometimes we come across a real head-scratcher.
That happened this week, when we saw a retraction notice for a 2015 paper on gastric cancer in the International Journal of Clinical and Experimental Medicine, which only says the authors “made big mistakes” and contains two fairly significant typos.
Although there’s no sign of a retraction on PubMed, the table of contents for the latest issue of the journal lists the retraction — but includes no hyperlink to the notice. The only way to see it is via a Web cached version. Here’s the text:
Sometime in the middle of 2015, Jennifer Byrne, professor of molecular oncology at the University of Sydney, began her journey from cancer researcher to a scientific literature sleuth, seeking out potentially problematic papers.
The first step was when she noticed several papers that contained a mistake in a DNA construct which, she believed, meant the papers were not testing the gene in question, associated with multiple cancer types. She started a writing campaign to the journal editors and researchers, with mixed success. But less than two years later, two of the five papers she flagged have already been retracted.
When asked why she spent time away from bench research to examine this issue, Byrne told us: Read the rest of this entry »
Nearly five years ago, researchers suggested that the vast majority of preclinical cancer research wouldn’t hold up to follow-up experiments, delaying much needed treatments for patients. In a series of articles publishing tomorrow morning, eLife has released the results of the first five attempts to replicate experiments in cancer biology — and the results are decidedly mixed.
As our co-founders Adam Marcus and Ivan Oransky write in STAT, the overall take-home message was that two studies generated findings similar to the original, one did not replicate the original, and two others were inconclusive.
They quote Brian Nosek, a psychologist at the University of Virginia, in Charlottesville, who runs the Center for Open Science, who has been leading the replication effort in his own field:
Last year, Pfizer fired one of its scientists following an investigation that ended with requests for retraction of five of her studies. Now, two of the five papers, which were first flagged on PubPeer, have been retracted.
One notice cites the Pfizer investigation, which found that cancer researcher Min-Jean Yin had included duplicated images in all five papers. Yin is the last author on both retracted papers.
Here’s the first notice from Clinical Cancer Research, which says most or all of the questioned images appear to be duplicates, and Pfizer — who sponsored the study and requested the retraction — can’t find the originals:
Read the rest of this entry »